The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients

Diabetes Care. 2001 May;24(5):953-4. doi: 10.2337/diacare.24.5.953.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Endothelial Growth Factors / blood*
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Lymphokines / blood*
  • Metformin / therapeutic use*
  • Pioglitazone
  • Thiazoles / therapeutic use*
  • Thiazolidinediones*
  • Time Factors
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Substances

  • Endothelial Growth Factors
  • Hypoglycemic Agents
  • Lymphokines
  • Thiazoles
  • Thiazolidinediones
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Metformin
  • Pioglitazone